Toronto Dominion Bank
CRSP icon

Toronto Dominion Bank’s CRISPR Therapeutics CRSP Stock Holding History

Toronto Dominion Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4
Closed -$216 – 1218
2024
Q2 		$216 Hold
4
– – ﹤0.01% 1312
2024
Q1 		$273 Hold
4
– – ﹤0.01% 1278
2023
Q4 		$250 Hold
4
– – ﹤0.01% 1394
2023
Q3 		$182 Buy
+4
New +$207 ﹤0.01% 1602

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Toronto Dominion Bank's CRSP Position: Q3 2024 in Review

Toronto Dominion Bank sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 4 shares — an estimated $216 sold.

Toronto Dominion Bank first reported a position in CRSP in Q3 2023 and held it in 4 quarters. The position peaked at $273 in Q1 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Toronto Dominion Bank reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Toronto Dominion Bank sold 4 CRISPR Therapeutics shares in Q3 2024, an estimated $216.
  • Toronto Dominion Bank first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 4 quarters.
  • Toronto Dominion Bank's CRISPR Therapeutics position peaked at $273 in Q1 2024.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Toronto Dominion Bank's 13F filing for Q3 2024, filed 14 Nov 2024.